Hepatitis C constitutes an infectious disease that causes severe damages to the liver, and is caused by hepatitis C
virus. There is no vaccine against this type of disease and the number of people infected continues to grow worldwide. The
anti-viral therapy which is currently used is a mixture of interferon alpha-2a with ribavirin, but approximately half of the
patients do not respond to therapy. Therefore, it is necessary to search for new compounds with anti-hepatitis C activity.
Computer-aided drug design methodologies have been vital in the discovery of candidates to drugs. This review is dedicated
to the role of computer-aided drug design methodologies for the development of new anti-hepatitis C agents. In addition, we
introduce a QSAR model based on substructural approaches in order to model the anti-hepatitis C activity in vivo.
Keywords: Anti-HCV agents, QSAR, 3D-QSAR, structure-based drug design, linear discriminant analysis, fragments
open access plus
Rights & PermissionsPrintExport